45 Wiggins Avenue
Bedford, MA 01730
United States
781 430 8200
https://www.stoketherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 110
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Edward M. Kaye M.D., Ph.D. | CEO & Director | 872.05k | N/A | 1949 |
Dr. Adrian R. Krainer Ph.D. | Co-Founder & Independent Director | 40.44k | N/A | 1959 |
Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer | 629.11k | N/A | 1961 |
Ms. Isabel Aznarez Ph.D. | Co-Founder & Senior VP of Discovery Research | N/A | N/A | 1972 |
Mr. Thomas Edward Leggett | Chief Financial Officer | N/A | N/A | 1977 |
Dr. Huw M. Nash Ph.D. | COO & Chief Business Officer | 394.87k | N/A | 1967 |
Mr. Eric Rojas | Head of Investor Relations | N/A | N/A | N/A |
Mr. Jonathan Allan J.D. | Corporate Secretary & General Counsel | N/A | N/A | 1990 |
Ms. Dawn Kalmar | Chief Communications Officer | N/A | N/A | 1978 |
Ms. Joan Wood | Chief Human Resources Officer | N/A | N/A | N/A |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 10.